Samsung Biologics named to Fortune Future 50

All News 11:47 October 19, 2018

SEOUL, Oct. 19 (Yonhap) -- Samsung BioLogics, a biopharmaceutical unit of South Korea's top conglomerate, Samsung Group, said Friday that it was named to Fortune's Future 50 list of companies with strong future growth prospects.

Fortune, in partnership with Boston Consulting Group, has selected Future 50 since last year to pick 50 global companies every year with the best prospects for long-term growth.

Among the listed companies are Alphabet Inc., Netflix and China-based Alibaba Group Holding.

"Fortune Future 50 again proves Samsung BioLogics' growth potential in the global market," said CEO Kim Tae-han in a press release. "The company will continue to make full efforts to grow into the leading global biopharmaceutical drug development and manufacturing company that can help not only customers but also patients."

Samsung BioLogics currently manufactures products for prominent global pharmaceutical brands, such as U.S.-based Bristol-Myers Squibb and Switzerland-based Roche Holding. The company is at the forefront of Samsung Group's quest for new growth engines.